NPs Basic Information
|
Name |
Talarolutin B
|
| Molecular Formula | C21H32O5 | |
| IUPAC Name* |
(1R,2S,3S,5R,7S,10R,14R)-3,5-dihydroxy-2,6,6,10,14-pentamethyl-11,13-dioxatetracyclo[8.8.0.02,7.012,17]octadec-12(17)-en-16-one
|
|
| SMILES |
C[C@@H]1CC(=O)C2=C(O1)O[C@@]3(CC[C@@H]4[C@@]([C@H]3C2)([C@H](C[C@H](C4(C)C)O)O)C)C
|
|
| InChI |
InChI=1S/C21H32O5/c1-11-8-13(22)12-9-15-20(4,26-18(12)25-11)7-6-14-19(2,3)16(23)10-17(24)21(14,15)5/h11,14-17,23-24H,6-10H2,1-5H3/t11-,14+,15+,16-,17+,20-,21+/m1/s1
|
|
| InChIKey |
IUVZTUKGYOYDHT-XMEPTYLDSA-N
|
|
| Synonyms |
alarolutin B; Talarolutin B; J3.580.495A
|
|
| CAS | NA | |
| PubChem CID | 132529126 | |
| ChEMBL ID | NA |
*Note: the IUPAC Name was collected from PubChem.
Chemical Classification: |
|
|
|---|
——————————————————————————————————————————
NPs Species Source
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
NPs Biological Activity
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
NPs Physi-Chem Properties
| Molecular Weight: | 364.5 | ALogp: | 2.6 |
| HBD: | 2 | HBA: | 5 |
| Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 76.0 | Aromatic Rings: | 4 |
| Heavy Atoms: | 26 | QED Weighted: | 0.685 |
——————————————————————————————————————————
NPs ADMET Properties*
ADMET: Absorption
| Caco-2 Permeability: | -4.672 | MDCK Permeability: | 0.00008390 |
| Pgp-inhibitor: | 0.948 | Pgp-substrate: | 0.891 |
| Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.018 |
| 30% Bioavailability (F30%): | 0.676 |
——————————————————————————————————————————
ADMET: Distribution
| Blood-Brain-Barrier Penetration (BBB): | 0.81 | Plasma Protein Binding (PPB): | 57.09% |
| Volume Distribution (VD): | 0.729 | Fu: | 50.52% |
——————————————————————————————————————————
ADMET: Metabolism
| CYP1A2-inhibitor: | 0.013 | CYP1A2-substrate: | 0.091 |
| CYP2C19-inhibitor: | 0.027 | CYP2C19-substrate: | 0.431 |
| CYP2C9-inhibitor: | 0.033 | CYP2C9-substrate: | 0.047 |
| CYP2D6-inhibitor: | 0.004 | CYP2D6-substrate: | 0.048 |
| CYP3A4-inhibitor: | 0.154 | CYP3A4-substrate: | 0.385 |
——————————————————————————————————————————
ADMET: Excretion
| Clearance (CL): | 7.192 | Half-life (T1/2): | 0.45 |
——————————————————————————————————————————
ADMET: Toxicity
| hERG Blockers: | 0.061 | Human Hepatotoxicity (H-HT): | 0.312 |
| Drug-inuced Liver Injury (DILI): | 0.042 | AMES Toxicity: | 0.013 |
| Rat Oral Acute Toxicity: | 0.785 | Maximum Recommended Daily Dose: | 0.983 |
| Skin Sensitization: | 0.396 | Carcinogencity: | 0.16 |
| Eye Corrosion: | 0.004 | Eye Irritation: | 0.02 |
| Respiratory Toxicity: | 0.972 |
——————————————————————————————————————————
*Note: the ADMET properties was calculated by ADMETlab 2.0. Reference: PMID: 33893803.
Similar Compounds*
Compounds similar to EMNPD with top10 similarity:
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC003406 |  |
0.707 | D0W2EK |  |
0.291 | ||
| ENC003408 |  |
0.521 | D04VIS |  |
0.266 | ||
| ENC003409 |  |
0.505 | D0Y2YP |  |
0.262 | ||
| ENC002748 |  |
0.400 | D06IIB |  |
0.262 | ||
| ENC002831 |  |
0.385 | D0Q6NZ |  |
0.259 | ||
| ENC001452 |  |
0.368 | D0P0HT |  |
0.257 | ||
| ENC003564 |  |
0.351 | D02JNM |  |
0.256 | ||
| ENC003581 |  |
0.351 | D04SFH |  |
0.255 | ||
| ENC002924 |  |
0.347 | D0D2TN |  |
0.254 | ||
| ENC003007 |  |
0.347 | D0L2LS |  |
0.250 | ||